Analysis Version
v1
History
Back to Study: Evolocumab to Reduce First Major Cardiovascular Ev...
causal
Analysis v1
Strong Support

For people with diabetes who are at high heart risk but don’t yet have serious artery disease, adding a drug called evolocumab to their cholesterol medicine (statin) cuts their chance of having a first heart attack, stroke, or heart-related death by about a third over nearly 5 years.

55
Pro
0
Against

Evidence from Studies

Supporting (1)

55

Community contributions welcome

55

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Randomized Controlled Trial
Human
2026 Mar 28

The study tested the exact same drug and patient group as in the claim and found that it reduced heart problems by 31%, just like the claim says.

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Score: 55
DOI: 10.1001/jama.2026.3277

Similar Assertions

For people with diabetes who are at high heart risk but don’t yet have major artery blockages, adding a drug called evolocumab to their usual cholesterol medicine cuts their chance of heart attack, stroke, or heart-related death by about a third over nearly 5 years.

55
0
96%

For people with diabetes but no major heart artery disease, adding a drug called evolocumab to their cholesterol medicine might lower their chance of dying over five years — 7.8% of those on the drug died, compared to 10.1% on a placebo.

55
0
94%

For people with diabetes who don’t have serious artery disease, adding a drug called evolocumab to their usual cholesterol medicine lowers bad cholesterol a lot — down to 52, compared to 111 without it — after a year.

55
0
91%

For people with heart disease who are already taking cholesterol-lowering statins but still have high LDL, adding a drug called evolocumab can lower their chances of having a heart attack, stroke, or other serious heart problems by about 15% over two years.

74
0
90%

Adding a drug called evolocumab to cholesterol-lowering statins can lower the chances of serious heart problems by 20% in people who already have heart disease.

79
0
89%